Badreddin Edris

2.8k total citations
17 papers, 951 citations indexed

About

Badreddin Edris is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Badreddin Edris has authored 17 papers receiving a total of 951 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Badreddin Edris's work include Sarcoma Diagnosis and Treatment (8 papers), Immune Cell Function and Interaction (4 papers) and Immune cells in cancer (3 papers). Badreddin Edris is often cited by papers focused on Sarcoma Diagnosis and Treatment (8 papers), Immune Cell Function and Interaction (4 papers) and Immune cells in cancer (3 papers). Badreddin Edris collaborates with scholars based in United States, Canada and Australia. Badreddin Edris's co-authors include Matt van de Rijn, Robert B. West, Andrew H. Beck, Kelli Montgomery, Shirley Zhu, Jonathan A. Fletcher, Sushama Varma, Rui Li, Robert J. Marinelli and Irving L. Weissman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Badreddin Edris

17 papers receiving 934 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Badreddin Edris United States 11 390 318 311 269 259 17 951
Tom Lesluyes France 18 353 0.9× 280 0.9× 72 0.2× 230 0.9× 325 1.3× 38 816
Takuji Mori Japan 16 513 1.3× 515 1.6× 245 0.8× 254 0.9× 181 0.7× 31 1.0k
Paolo Cotzia United States 17 364 0.9× 363 1.1× 163 0.5× 272 1.0× 439 1.7× 34 1.1k
Jennifer Cain United States 11 671 1.7× 470 1.5× 181 0.6× 149 0.6× 104 0.4× 19 1.1k
Rindert Missiaen United States 8 432 1.1× 449 1.4× 336 1.1× 265 1.0× 155 0.6× 9 962
Francesca Simionato Italy 17 290 0.7× 455 1.4× 111 0.4× 199 0.7× 199 0.8× 31 794
Gabriella Gaudioso Italy 16 369 0.9× 221 0.7× 80 0.3× 228 0.8× 156 0.6× 29 778
Sung‐Im Do South Korea 16 399 1.0× 340 1.1× 84 0.3× 258 1.0× 175 0.7× 84 913
Mari Nishio Japan 17 359 0.9× 462 1.5× 434 1.4× 178 0.7× 154 0.6× 42 971

Countries citing papers authored by Badreddin Edris

Since Specialization
Citations

This map shows the geographic impact of Badreddin Edris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Badreddin Edris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Badreddin Edris more than expected).

Fields of papers citing papers by Badreddin Edris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Badreddin Edris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Badreddin Edris. The network helps show where Badreddin Edris may publish in the future.

Co-authorship network of co-authors of Badreddin Edris

This figure shows the co-authorship network connecting the top 25 collaborators of Badreddin Edris. A scholar is included among the top collaborators of Badreddin Edris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Badreddin Edris. Badreddin Edris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Fryzek, Jon P., Badreddin Edris, Michael Mørk Petersen, et al.. (2022). The epidemiology of desmoid tumors in Denmark. Cancer Epidemiology. 77. 102114–102114. 15 indexed citations
4.
Rosen, Ezra Y., Nenad Sarapa, Badreddin Edris, et al.. (2022). Abstract OT2-23-01: A Phase 1b/2a, open-label platform study to evaluate mirdametinib in combination with fulvestrant in ER+ metastatic breast cancers harboring MAPK-activating mutations. Cancer Research. 82(4_Supplement). OT2–23. 1 indexed citations
5.
Zhang, Xinwen, Rong Du, Wei Min, et al.. (2020). Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors. Cancer Research. 80(16_Supplement). 6415–6415. 4 indexed citations
6.
Keire, Paul, Steven L. Bressler, Joan M. Lemire, et al.. (2014). A Role for Versican in the Development of Leiomyosarcoma. Journal of Biological Chemistry. 289(49). 34089–34103. 26 indexed citations
7.
Garfin, Phillip M., Dullei Min, Jerrod L. Bryson, et al.. (2013). Inactivation of the RB family prevents thymus involution and promotes thymic function by direct control of Foxn1 expression. The Journal of Experimental Medicine. 210(6). 1087–1097. 53 indexed citations
8.
Edris, Badreddin, Stephen B. Willingham, Kipp Weiskopf, et al.. (2013). Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. OncoImmunology. 2(6). e24452–e24452. 3 indexed citations
9.
Edris, Badreddin, Stephen B. Willingham, Kipp Weiskopf, et al.. (2013). Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proceedings of the National Academy of Sciences. 110(9). 3501–3506. 44 indexed citations
10.
Edris, Badreddin, Íñigo Espinosa, Thomas Mühlenberg, et al.. (2012). ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. The Journal of Pathology. 227(2). 223–233. 66 indexed citations
11.
Edris, Badreddin, Kipp Weiskopf, Anne Kathrin Volkmer, et al.. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences. 109(17). 6656–6661. 211 indexed citations
12.
Edris, Badreddin, Kipp Weiskopf, Irving L. Weissman, & Matt van de Rijn. (2012). Flipping the script on macrophages in leiomyosarcoma. OncoImmunology. 1(7). 1202–1204. 8 indexed citations
13.
Edris, Badreddin, Jonathan A. Fletcher, Robert B. West, Matt van de Rijn, & Andrew H. Beck. (2012). Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma. Sarcoma. 2012. 1–9. 18 indexed citations
14.
Brunner, Alayne, Andrew H. Beck, Badreddin Edris, et al.. (2012). Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome biology. 13(8). R75–R75. 185 indexed citations
15.
Espinosa, Íñigo, Badreddin Edris, Cheng‐Han Lee, et al.. (2011). CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. American Journal Of Pathology. 179(4). 2100–2107. 32 indexed citations
16.
Beck, Andrew H., Íñigo Espinosa, Badreddin Edris, et al.. (2009). The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma. Clinical Cancer Research. 15(3). 778–787. 154 indexed citations
17.
Beck, Andrew H., Daniela Witten, Badreddin Edris, et al.. (2009). Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene. 29(6). 845–854. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tom Lesluyes Breakdown of academic impact, for papers by Takuji Mori Breakdown of academic impact, for papers by Paolo Cotzia Breakdown of academic impact, for papers by Jennifer Cain Breakdown of academic impact, for papers by Rindert Missiaen Breakdown of academic impact, for papers by Francesca Simionato Breakdown of academic impact, for papers by Gabriella Gaudioso Breakdown of academic impact, for papers by Sung‐Im Do Breakdown of academic impact, for papers by Mari Nishio
Rankless by CCL
2026